Which has preferable valuation & earnings, EWTX or ORIC?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A

Is EWTX or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Oric Pharmaceuticals N/A -35.35% -33.39%

Does the media prefer EWTX or ORIC?

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 4 mentions for Oric Pharmaceuticals and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat Oric Pharmaceuticals' score of 0.37 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ACAD or ORIC?

In the previous week, ACADIA Pharmaceuticals and ACADIA Pharmaceuticals both had 4 articles in the media. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat Oric Pharmaceuticals' score of 0.37 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation & earnings, PBLS or ORIC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A

Is PBLS or ORIC more profitable?

Parabilis Medicines' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Parabilis Medicines N/A N/A N/A Oric Pharmaceuticals N/A -35.35% -33.39%

Does the media prefer PBLS or ORIC?

In the previous week, Parabilis Medicines had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 5 mentions for Parabilis Medicines and 4 mentions for Oric Pharmaceuticals. Parabilis Medicines' average media sentiment score of 0.58 beat Oric Pharmaceuticals' score of 0.37 indicating that Parabilis Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is RLAY or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Oric Pharmaceuticals N/A -35.35% -33.39%

Does the media favor RLAY or ORIC?

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 4 mentions for Oric Pharmaceuticals and 2 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.77 beat Oric Pharmaceuticals' score of 0.37 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, CELC or ORIC?

Celcuity is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A

Is CELC or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Oric Pharmaceuticals N/A -35.35% -33.39%

Does the media favor CELC or ORIC?

In the previous week, Celcuity had 2 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Celcuity and 4 mentions for Oric Pharmaceuticals. Celcuity's average media sentiment score of 0.83 beat Oric Pharmaceuticals' score of 0.37 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Oric Pharmaceuticals (ORIC) Competitors

$12.79 -0.09 (-0.70%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.80 +0.02 (+0.12%)

As of 09/18/2026 06:26 PM Eastern

Compare

ORIC vs. EWTX, ACAD, PBLS, RLAY, and CELC

Should you buy Oric Pharmaceuticals stock or one of its competitors? Oric Pharmaceuticals's main competitors and comparable companies include Edgewise Therapeutics (EWTX), ACADIA Pharmaceuticals (ACAD), Parabilis Medicines (PBLS), Relay Therapeutics (RLAY), and Celcuity (CELC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oric Pharmaceuticals compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Oric Pharmaceuticals (NASDAQ:ORIC) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Edgewise Therapeutics presently has a consensus price target of $50.33, indicating a potential upside of 11.06%. Oric Pharmaceuticals has a consensus price target of $19.60, indicating a potential upside of 53.24%. Given Oric Pharmaceuticals' higher probable upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 4 mentions for Oric Pharmaceuticals and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat Oric Pharmaceuticals' score of 0.37 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Oric Pharmaceuticals' return on equity of -35.35% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Edgewise Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

Summary

Oric Pharmaceuticals beats Edgewise Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Oric Pharmaceuticals (NASDAQ:ORIC) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

ACADIA Pharmaceuticals currently has a consensus target price of $34.36, indicating a potential upside of 25.91%. Oric Pharmaceuticals has a consensus target price of $19.60, indicating a potential upside of 53.24%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.39	$391M	$2.22	12.29
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

In the previous week, ACADIA Pharmaceuticals and ACADIA Pharmaceuticals both had 4 articles in the media. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat Oric Pharmaceuticals' score of 0.37 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Oric Pharmaceuticals' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Oric Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and Oric Pharmaceuticals (NASDAQ:ORIC) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Parabilis Medicines had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 5 mentions for Parabilis Medicines and 4 mentions for Oric Pharmaceuticals. Parabilis Medicines' average media sentiment score of 0.58 beat Oric Pharmaceuticals' score of 0.37 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Parabilis Medicines presently has a consensus target price of $41.67, suggesting a potential downside of 0.15%. Oric Pharmaceuticals has a consensus target price of $19.60, suggesting a potential upside of 53.24%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Parabilis Medicines' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Parabilis Medicines and Oric Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Oric Pharmaceuticals (NASDAQ:ORIC) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Oric Pharmaceuticals has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	268.96	-$276.48M	-$1.57	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 4 mentions for Oric Pharmaceuticals and 2 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.77 beat Oric Pharmaceuticals' score of 0.37 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Relay Therapeutics currently has a consensus target price of $25.92, suggesting a potential upside of 37.56%. Oric Pharmaceuticals has a consensus target price of $19.60, suggesting a potential upside of 53.24%. Given Oric Pharmaceuticals' higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Oric Pharmaceuticals' return on equity of -35.35% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Relay Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Oric Pharmaceuticals beats Relay Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Celcuity?

Celcuity (NASDAQ:CELC) and Oric Pharmaceuticals (NASDAQ:ORIC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Celcuity presently has a consensus price target of $154.75, indicating a potential upside of 91.97%. Oric Pharmaceuticals has a consensus price target of $19.60, indicating a potential upside of 53.24%. Given Celcuity's stronger consensus rating and higher possible upside, equities research analysts clearly believe Celcuity is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Celcuity has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

Oric Pharmaceuticals' return on equity of -35.35% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Celcuity is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

63.3% of Celcuity shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 13.3% of Celcuity shares are held by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Celcuity had 2 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Celcuity and 4 mentions for Oric Pharmaceuticals. Celcuity's average media sentiment score of 0.83 beat Oric Pharmaceuticals' score of 0.37 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Oric Pharmaceuticals beats Celcuity on 8 of the 13 factors compared between the two stocks.

Get Oric Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORIC vs. The Competition

Export

Metric	Oric Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.34B	$3.92B	$7.25B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-9.47	14.30	275.79	25.40
Price / Sales	N/A	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	3.28	15.45	10.46	6.33
Net Income	-$129.47M	-$22.86M	$3.49B	$358.33M
7 Day Performance	6.23%	-1.21%	0.59%	1.12%
1 Month Performance	-12.70%	-4.42%	-2.01%	-2.67%
1 Year Performance	21.12%	37.81%	18.09%	6.01%

Oric Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORIC Oric Pharmaceuticals	2.3366 of 5 stars	$12.79 -0.7%	$19.60 +53.2%	+16.3%	$1.34B	N/A	N/A	111	High Trading Volume
EWTX Edgewise Therapeutics	2.4456 of 5 stars	$44.62 +0.5%	$50.33 +12.8%	+191.8%	$4.82B	N/A	N/A	127	Positive News Options Volume
ACAD ACADIA Pharmaceuticals	4.436 of 5 stars	$27.52 -1.1%	$34.36 +24.9%	+10.3%	$4.80B	$1.07B	12.40	798	Positive News
PBLS Parabilis Medicines	1.5724 of 5 stars	$36.16 -2.0%	$41.67 +15.2%	N/A	$4.56B	$148K	N/A	145	News Coverage
RLAY Relay Therapeutics	2.3994 of 5 stars	$19.06 +1.0%	$25.92 +36.0%	+314.1%	$4.14B	$10.35M	N/A	192

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORIC) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. EWTX, ACAD, PBLS, RLAY, and CELC

How does Oric Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does Oric Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

How does Oric Pharmaceuticals compare to Parabilis Medicines?

Summary

How does Oric Pharmaceuticals compare to Relay Therapeutics?

Summary

How does Oric Pharmaceuticals compare to Celcuity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. EWTX, ACAD, PBLS, RLAY, and CELC

How does Oric Pharmaceuticals compare to Edgewise Therapeutics?

Do analysts prefer EWTX or ORIC?

Does the media prefer EWTX or ORIC?

Is EWTX or ORIC more profitable?

Which has preferable valuation & earnings, EWTX or ORIC?

Do institutionals & insiders believe in EWTX or ORIC?

Which has more volatility & risk, EWTX or ORIC?

Summary

How does Oric Pharmaceuticals compare to ACADIA Pharmaceuticals?

Do analysts prefer ACAD or ORIC?

Which has more risk and volatility, ACAD or ORIC?

Which has better valuation & earnings, ACAD or ORIC?

Does the media refer more to ACAD or ORIC?

Is ACAD or ORIC more profitable?

Do insiders & institutionals believe in ACAD or ORIC?

Summary

How does Oric Pharmaceuticals compare to Parabilis Medicines?

Does the media prefer PBLS or ORIC?

Which has higher valuation & earnings, PBLS or ORIC?

Do analysts prefer PBLS or ORIC?

Is PBLS or ORIC more profitable?

Do insiders & institutionals have more ownership in PBLS or ORIC?

Summary

How does Oric Pharmaceuticals compare to Relay Therapeutics?

Which has stronger earnings and valuation, RLAY or ORIC?

Does the media favor RLAY or ORIC?

Do analysts recommend RLAY or ORIC?

Is RLAY or ORIC more profitable?

Which has more risk & volatility, RLAY or ORIC?

Do institutionals and insiders have more ownership in RLAY or ORIC?

Summary

How does Oric Pharmaceuticals compare to Celcuity?

Do analysts recommend CELC or ORIC?

Which has more risk & volatility, CELC or ORIC?

Is CELC or ORIC more profitable?

Which has better valuation and earnings, CELC or ORIC?

Do insiders & institutionals hold more shares of CELC or ORIC?

Does the media favor CELC or ORIC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools